The eBooks we sell are sold as a single-user licence and are intended for the end user only.
The sale of some eBooks are restricted to certain countries. To alert you to such restrictions, please select the country of the billing address of your credit or debit card you wish to use for payment.
For further information see https://www.wildy.com/ebook-formats
Once the order is confirmed an e-mail will be sent to you to allow you to download the eBook. For UK purchases this will be automatic. For purchases outside the UK a member of staff will need to confirm the sale. (Staff are available to do this during normal business hours, Mon-Fri 8:30-17:00 UK time)
All eBooks are supplied firm sale and cannot be returned. If you believe there is a fault with your eBook then contact us on ebooks@wildy.com and we will help in resolving the issue. This does not affect your statutory rights.
Due to a technical issue some ebooks are not available to order.
The drug control regime established by the international community has not succeeded in curbing either the demand for, or the offer of, narcotics. But, despite a series of developments in the Americas - including the legalisation of cannabis in Uruguay, as well as in Colorado - there is still little support in Europe for repealing drug-prohibition laws. Nevertheless, a gradual policy convergence reveals the emergence of a European model favouring public-health strategies over a strictly penal approach to combating drugs; whilst growing trans-national support for legalisation indicates the persistence of an alternative paradigm for drug policy.
This book examines the various influences on drug policies in Europe: as the impetus for drug policy changes from grassroots movements, NGO networks, private foundations and academic research centres among others, are increasingly confronting the prevailing discourses of drug prohibition and criminalisation. Pursuing an interdisciplinary approach, and bringing together legal scholars, social scientists and practitioners, it provides a comprehensive, and critical, assessment of on drug policy reform in Europe.
